비흑색종 피부암 치료 시장 규모, 점유율, 동향 및 예측 : 치료법별, 적응증별, 최종 용도별, 지역별(2026-2034년)

The global non-melanoma skin cancer treatment market size was valued at USD 614.2 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 881.5 Million by 2034, exhibiting a CAGR of 4.10% from 2026-2034. North America currently dominates the market, holding a market share of 42% in 2025. The region benefits from advanced healthcare infrastructure, high skin cancer diagnosis rates, widespread adoption of innovative treatment modalities, strong research funding from government and private institutions, and favorable reimbursement policies that facilitate patient access to cutting-edge therapies, all contributing to the non-melanoma skin cancer treatment market share.

The increasing incidence of non-melanoma skin cancers worldwide, especially basal cell carcinoma and squamous cell carcinoma, is a major driving force for the growth of the non-melanoma skin cancer treatment market. The increasing exposure to ultraviolet radiation due to ozone layer depletion, as well as lifestyle changes that include increased outdoor exposure, and the growing geriatric population with increased susceptibility to skin malignancies are also contributing factors to the increasing demand for effective treatment options. Advances in radiation therapy technology, such as brachytherapy and intensity-modulated radiation therapy, are also improving the accuracy of treatment and patient outcomes. In addition, the increasing use of photodynamic therapy and the development of new immunotherapeutic agents are also expanding the treatment options. Increasing healthcare spending, increased awareness of early skin cancer detection, and government-sponsored screening programs are also fueling the growth of the market. The use of artificial intelligence in diagnostic imaging is also improving clinical decision-making and treatment planning.

The United States has turned out to be a prominent area in the non-melanoma skin cancer treatment market due to a number of reasons. The United States has one of the highest rates of skin cancer incidence in the world due to substantial exposure to ultraviolet radiation, an aging population, and a predominantly fair-skinned population. The well-developed healthcare infrastructure, widespread health insurance coverage, and high patient awareness regarding skin cancer screening have contributed to early diagnosis and treatment. In addition, the non-melanoma skin cancer treatment market outlook is aided by strong research and development, with the top academic medical institutions investing in the development of next-generation therapies. The presence of advanced radiation equipment, increasing use of Mohs micrographic surgery, and favorable approval processes for new drugs further enhance the position of the United States in the non-melanoma skin cancer treatment market. Furthermore, increased public health initiatives to encourage regular dermatological checks and sun protection measures are increasing early intervention rates in the United States.

NON-MELANOMA SKIN CANCER TREATMENT MARKET TRENDS:

Expanding Immunotherapy Treatment Options

The increasing development and regulatory approval of immunotherapeutic agents for non-melanoma skin cancers is significantly transforming the treatment landscape. Immune checkpoint inhibitors targeting the PD-1 pathway have demonstrated remarkable efficacy in managing advanced cutaneous squamous cell carcinoma and basal cell carcinoma, offering patients new therapeutic options beyond traditional surgery and radiation. These agents work by restoring the immune system's ability to recognize and destroy cancer cells, leading to improved disease-free survival outcomes. For instance, in October 2025, the US FDA approved cemiplimab-rwlc as the first immunotherapy for adjuvant treatment of high-risk cutaneous squamous cell carcinoma following surgery and radiation, demonstrating a reduction in the risk of disease recurrence or death. The growing pipeline of immunotherapy combinations and the exploration of neoadjuvant applications are further expanding the non-melanoma skin cancer treatment market forecast.

Advancing Radiation Therapy Technologies

Significant technological advancements in radiation therapy are enhancing treatment precision and patient outcomes in non-melanoma skin cancer management. Modern radiotherapeutic modalities, including brachytherapy, proton beam therapy, and volumetric modulated arc therapy, enable clinicians to deliver highly targeted doses while minimizing damage to surrounding healthy tissues. Radiation therapy has demonstrated efficacy in treating non-melanoma skin cancers and is particularly beneficial for patients who are not surgical candidates or have tumors in cosmetically sensitive areas. For instance, a 2025 clinical study published in Advances in Radiation Oncology reported that Rhenium-skin cancer therapy achieved a 94.1 percent complete response rate across 185 treated lesions in a single outpatient session. These innovations in radiation delivery systems are driving significant demand and supporting the non-melanoma skin cancer treatment market trends across global healthcare settings.

Rising Early Detection and Screening

The increasing emphasis on early detection and screening programs for skin cancer is driving treatment demand and improving patient outcomes worldwide. Governments and healthcare organizations are investing in public awareness campaigns, dermatological screening initiatives, and digital health technologies to facilitate earlier identification of non-melanoma skin cancers. Advanced diagnostic tools, including artificial intelligence-powered imaging systems and teledermatology platforms, are enabling more accurate and accessible skin cancer detection, particularly in underserved regions. For instance, according to the GLOBOCAN 2022 data, approximately 1,234,533 people were diagnosed with non-melanoma skin cancer globally, ranking it as the fifth most common cancer worldwide. This substantial disease burden is prompting healthcare systems to strengthen early intervention strategies and expand treatment infrastructure, thereby supporting sustained growth in the non-melanoma skin cancer treatment market growth opportunities.

NON-MELANOMA SKIN CANCER TREATMENT INDUSTRY SEGMENTATION:

Analysis by Treatment Type:

• Chemotherapy
• Radiation Therapy
• Photodynamic Therapy
• Others

Radiation therapy holds 39% of the market share. Radiation therapy is an important treatment option for non-melanoma skin cancers and provides effective tumor control for patients who are not ideal candidates for surgical treatment or have lesions in difficult anatomical sites. Radiation therapy includes different modalities such as external beam radiation, brachytherapy, and superficial radiation therapy, which are designed for specific tumor properties and patient needs. Radiation therapy is most commonly used for elderly patients and patients with multiple comorbidities, for whom the risk of surgery is high. The increasing use of advanced linear accelerators and advancements in image-guided treatment planning are further solidifying the leading market position of the segment. Moreover, advancements in adaptive radiotherapy and the development of precision-focused delivery systems are allowing radiation oncologists to deliver the maximum dose to the tumor while sparing the surrounding healthy tissues. The increasing development of outpatient radiation facilities and the increasing reimbursement support for non-invasive treatment modalities are further supporting the adoption of radiation therapy in different healthcare settings.

Analysis by Indication:

• Basal Cell Carcinoma
• T-Cell Lymphoma
• Squamous Cell Carcinoma
• Others

Basal cell carcinoma leads the market with a share of 65%. Basal cell carcinoma is the most common type of non-melanoma skin cancer, which originates from the basal cells of the epidermis and usually manifests as slowly growing and locally invasive neoplasms. The disease is a known consequence of cumulative exposure to ultraviolet radiation and is most common in fair-skinned populations in areas with high sun exposure. Current treatment modalities include surgical excision, Mohs micrographic surgery, radiation therapy, topical therapy, and hedgehog pathway inhibitors for advanced disease. The sheer dominance of basal cell carcinoma among all non-melanoma skin cancers translates to a huge demand for various treatment options. The dominance of this market segment is maintained by the increasing incidence rates, improved access to treatment, and increasing awareness about early skin examination practices. Moreover, recent developments in targeted therapies and the increasing use of minimally invasive techniques are expanding the treatment options. The expanding geriatric population with heightened susceptibility to cumulative sun damage and the improvement of diagnostic capabilities in primary care settings are further reinforcing the leading position of this segment.

Analysis by End Use:

• Hospitals
• Specialty Clinics
• Ambulatory Surgery Centers
• Others

Hospitals dominate the market, with a share of 49%. Hospitals are the main treatment centers for non-melanoma skin cancer, thanks to their comprehensive infrastructure, multidisciplinary staff, and availability of advanced treatment technologies. The hospitals provide a complete range of treatment modalities, including surgical procedures, radiation therapy facilities, photodynamic therapy stations, and systemic therapy administration. The hospitals are especially important for the treatment of complex and advanced cases that require a multidisciplinary approach involving specialties such as dermatology, oncology, pathology, and plastic surgery. The availability of advanced diagnostic equipment, imaging facilities, and inpatient services makes hospitals the preferred treatment centers for comprehensive skin cancer care. Furthermore, the increasing use of electronic health records and clinical decision support systems in hospital settings is improving treatment standardization and patient management. The rising trend of setting up skin cancer units in hospital oncology divisions and the expansion of outpatient treatment services in hospitals are further solidifying the dominance of this market segment in the overall market dynamics.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance in the market with a 42% market share. The dominance of the region is fueled by the high prevalence of non-melanoma skin cancer among the predominantly fair-skinned population, along with the advanced healthcare infrastructure and research capabilities. North America enjoys the presence of large pharmaceutical and medical device companies that are constantly working on the development of innovative treatment options, well-structured reimbursement systems that make it easy for patients to access treatments, and generous government support for cancer research. In addition, the region's widespread presence of specialized cancer care facilities and high awareness levels about skin cancer screening are also responsible for early detection and comprehensive treatment of patients. The presence of advanced radiation therapy equipment, widespread use of Mohs micrographic surgery, and increasing use of immunotherapeutic agents are also enhancing the treatment environment in the region. In addition, the supportive regulatory framework that promotes expedited approval routes for new cancer therapies and the increasing use of digital health technologies in dermatology are also solidifying North America's position as a leader in the global non-melanoma skin cancer treatment market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES NON-MELANOMA SKIN CANCER TREATMENT MARKET ANALYSIS

The United States is the largest and most impactful market for non-melanoma skin cancer treatment in North America, due to the presence of an exceptionally high prevalence rate of the disease, an advanced medical infrastructure, and a strong focus on innovation in cancer treatment. The United States has a well-structured healthcare system that offers access to a broad range of skin cancer treatments, including surgical excision, Mohs micrographic surgery, radiation therapy, photodynamic therapy, and promising immunotherapies. The country's healthcare system has extensive health insurance coverage that makes it possible for patients to access both established and emerging therapies. The presence of top-class academic medical institutions and cancer research organizations in the United States fuels ongoing innovation in treatment approaches. Moreover, the country's FDA has favorable procedures for fast-track approval of new drugs, an increasing focus on personalized medicine, and public awareness campaigns regarding skin cancer prevention and early diagnosis, which further consolidate the United States market and expedite the adoption of therapies across the healthcare spectrum.

EUROPE NON-MELANOMA SKIN CANCER TREATMENT MARKET ANALYSIS

Europe represents a significant market for non-melanoma skin cancer treatment, supported by well-developed healthcare systems, universal health coverage in many countries, and growing awareness about skin cancer prevention and screening. The region faces a rising skin cancer burden, driven by aging populations, historical outdoor lifestyle patterns, and cumulative ultraviolet radiation exposure among predominantly fair-skinned populations. European countries, particularly Germany, the United Kingdom, France, and Italy, maintain advanced oncology infrastructure with specialized dermatology centers and comprehensive treatment capabilities. For instance, according to an industry report, non-melanoma skin cancers in Europe are projected to increase in incidence by approximately 40 percent by 2040, with associated mortality rising by around 50 percent. The European Medicines Agency's proactive regulatory framework and growing emphasis on immunotherapy approvals, including the recent positive opinion for cemiplimab as adjuvant treatment for high-risk cutaneous squamous cell carcinoma, are further expanding treatment options and market potential across the region.

ASIA-PACIFIC NON-MELANOMA SKIN CANCER TREATMENT MARKET ANALYSIS

The Asia-Pacific region is emerging as a significant growth market for non-melanoma skin cancer treatment, driven by rising skin cancer incidence, improving healthcare infrastructure, and increasing awareness about early detection and treatment. Countries such as Australia, Japan, South Korea, and China are leading regional market development through expanding oncology facilities and growing adoption of advanced treatment technologies. For instance, according to the Global Burden of Disease Study, East Asia experienced the highest growth rate in skin cancer incidence globally from 1990 to 2021, with an estimated annual percentage change of 4.42 percent. The region's expanding dermatology workforce, increasing government investment in cancer care programs, and growing access to radiation therapy and immunotherapy are driving sustained market expansion.

LATIN AMERICA NON-MELANOMA SKIN CANCER TREATMENT MARKET ANALYSIS

Latin America is witnessing growing demand for non-melanoma skin cancer treatment, supported by increasing disease awareness, expanding healthcare infrastructure, and rising healthcare expenditure across the region. Brazil and Mexico represent the largest markets, benefiting from improving access to oncology services and growing investment in advanced treatment technologies. The incidence of non-melanoma skin cancers in Latin America continues to rise, driven by high ultraviolet radiation exposure in tropical and subtropical zones. Government-led screening initiatives and expanding public health programs are enhancing early detection and treatment uptake throughout the region.

MIDDLE EAST AND AFRICA NON-MELANOMA SKIN CANCER TREATMENT MARKET ANALYSIS

The Middle East and Africa region is gradually expanding its non-melanoma skin cancer treatment market, driven by increasing awareness, improving diagnostic capabilities, and growing healthcare infrastructure. While skin cancer incidence rates in the region are relatively lower compared to North America and Europe, rising ultraviolet exposure and population growth are contributing to increasing case numbers. According to a study on global skin cancer patterns, despite relatively lower incidence rates in Africa, non-melanoma skin cancer mortality rates remain notable due to delayed diagnosis and limited treatment access. Ongoing investments in healthcare modernization and the establishment of specialized oncology centers are expected to support market growth.

COMPETITIVE LANDSCAPE:

The competitive environment of the global non-melanoma skin cancer treatment market is marked by the involvement of prominent pharmaceutical companies, medical device manufacturers, and biotech companies in the development and commercialization of innovative treatment options. Major players in the market are making efforts to enhance their oncology pipelines through strategic acquisitions, licensing agreements, and research collaborations to improve treatment outcomes. Substantial investments are being made by companies in clinical trials of new immunotherapies, targeted therapies, and advanced radiation therapy platforms to meet the unmet medical needs of patients. The approval of cemiplimab as adjuvant immunotherapy has significantly changed treatment practices, and this has increased competition among companies developing PD-1 inhibitors. Moreover, companies are also making efforts to increase their presence in the global market through collaborations with local distributors and healthcare organizations, especially in emerging markets with rising demand for advanced skin cancer treatment options.

The report provides a comprehensive analysis of the competitive landscape in the non-melanoma skin cancer treatment market with detailed profiles of all major companies, including:

• Accuray Incorporated
• Almirall S.A.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Elekta AB
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Icad Inc.
• Merck & Co. Inc.
• Novartis AG
• Sun Pharmaceutical Industries Limited
• Varian Medical Systems Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the non-melanoma skin cancer treatment market?

2. What is the future outlook of non-melanoma skin cancer treatment market?

3. What are the key factors driving the non-melanoma skin cancer treatment market?

4. Which region accounts for the largest non-melanoma skin cancer treatment market share?

5. Which are the leading companies in the global non-melanoma skin cancer treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Non-Melanoma Skin Cancer Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Treatment Type

• 6.1 Chemotherapy
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Radiation Therapy
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Photodynamic Therapy
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Indication

• 7.1 Basal Cell Carcinoma
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 T-Cell Lymphoma
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Squamous Cell Carcinoma
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by End Use

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Specialty Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Ambulatory Surgery Centers
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Accuray Incorporated
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Almirall S.A.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Boehringer Ingelheim GmbH
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 SWOT Analysis
  • 14.3.4 Bristol-Myers Squibb Company
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Elekta AB
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Eli Lilly and Company
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 F. Hoffmann-La Roche AG
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Icad Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Merck & Co. Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Novartis AG
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Sun Pharmaceutical Industries Limited
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Varian Medical Systems Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis